Eli Lilly and Co (FRA:LLY0) Net Interest Margin (Bank Only) %


FRA:LLY0 Eli Lilly and Co FRA:LLY0
96 GF Score
Price €25.80
GF Value €32.68
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:LLY0
96GF Score
Eli Lilly and Co FRA:LLY0
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Eli Lilly and Co (FRA:LLY0) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of €25.80 is trading 21.1% below its estimated GF Value™ of €32.68. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for FRA:LLY0:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €32.68 vs. price of €25.80 (21.1% below fair value)
  • GF Score™: 96/100 with 6 warning signs

No single metric tells the full story. See the FRA:LLY0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
96GF Score

Get the complete analysis for FRA:LLY0

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€25.80
Price
€32.68
GF Value